Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of “Moderate Buy” by Brokerages

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has been assigned an average rating of “Moderate Buy” from the seven research firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $19.50.

A number of equities research analysts recently weighed in on the company. Wall Street Zen downgraded Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Friday, July 17th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, June 23rd.

Institutional Investors Weigh In On Enanta Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of ENTA. Hillsdale Investment Management Inc. acquired a new position in shares of Enanta Pharmaceuticals during the fourth quarter worth $6,660,000. Spruce Street Capital LP acquired a new stake in shares of Enanta Pharmaceuticals in the 2nd quarter worth $15,873,698. Janus Henderson Group PLC boosted its position in shares of Enanta Pharmaceuticals by 1.5% in the 1st quarter. Janus Henderson Group PLC now owns 3,784,055 shares of the biotechnology company’s stock worth $47,717,000 after purchasing an additional 54,396 shares in the last quarter. Jupiter Topco LLC purchased a new position in Enanta Pharmaceuticals during the 2nd quarter worth $53,252,000. Finally, ADAR1 Capital Management LLC purchased a new position in Enanta Pharmaceuticals during the 2nd quarter worth $19,603,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Stock Performance

NASDAQ ENTA opened at $14.08 on Monday. Enanta Pharmaceuticals has a one year low of $7.05 and a one year high of $17.15. The company has a market capitalization of $410.08 million, a price-to-earnings ratio of -5.84 and a beta of 0.93. The company’s 50-day simple moving average is $13.60 and its two-hundred day simple moving average is $13.47.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.16). The business had revenue of $14.36 million during the quarter, compared to analysts’ expectations of $16.76 million. Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%. Equities analysts expect that Enanta Pharmaceuticals will post -2.36 earnings per share for the current fiscal year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.